Au­to­lus claims a CAR-T win at EHA; Ima­go touts two PhII tri­al wins for rare dis­ease drug

Pre­sen­ta­tions at the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion be­gan Fri­day, with Au­to­lus Ther­a­peu­tics re­veal­ing da­ta they say con­tin­ue to show the ben­e­fit of their CAR-T pro­gram.

The Au­to­lus pro­gram, known as 0be-cel, achieved a 100% com­plete re­mis­sion rate in a co­hort of in­do­lent B Cell Non-Hodgkin lym­phoma pa­tients, with all nine treat­ed pa­tients hit­ting the mark as of the May 17 cut­off. An­oth­er three pa­tients are still await­ing treat­ment, while a fourth en­rolled in­di­vid­ual died due to a Covid-19 in­fec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER